Alembic Pharmaceuticals is an Indian pharmaceutical company that specializes in the development, manufacturing, and marketing of a diverse range of pharmaceutical products, including formulations and active pharmaceutical ingredients. Founded in 1907, the company has a strong focus on research and development, and has invested heavily in state-of-the-art facilities and advanced technologies to deliver high-quality products. Alembic Pharmaceuticals has a wide range of therapeutic products, including medicines for cardiovascular, anti-infective, gastroenterology, and central nervous system disorders, among others.
- ALEMBIC PHARMACEUTICALS LIMITED reported Total Income for Q4 FY23 of ₹1,407 Crore down from ₹1,426 Crore year on year, a negative growth of 1.3%.
- Total Expenses for Q4 FY23 of ₹1,288 Crore down from ₹1,385 Crore year on year, a negative growth of 7%.
- Consolidated Net Profit of ₹152 Crore, up 590% from ₹22 Crore in the same quarter of the previous year.
- The Earnings per Share is ₹7.76, up 599% from ₹1.11 in the same quarter of the previous year.